Theresa Heggie Sells 70,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director owned 65,352 shares of the company's stock, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.BioCryst Pharmaceuticals Stock PerformanceNASDAQ:BCRX opened at $8.45 on Friday. The company's 50-day simple moving average is $9.11 and its 200-day simple moving average is $8.77. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.01 and a fifty-two week high of $11.31. The stock has a market capitalization of $1.77 billion, a P/E ratio of -46.94, a P/E/G ratio of 1.94 and a beta of 1.10. BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analysts' expectations of $149.59 million. The company's revenue was up 49.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) EPS. On average, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year. Analysts Set New Price TargetsA number of equities research analysts recently weighed in on BCRX shares. Bank of America lifted their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, July 1st. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Cantor Fitzgerald assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $16.70.Read Our Latest Stock Report on BCRXInstitutional Trading of BioCryst PharmaceuticalsSeveral hedge funds and other institutional investors have recently made changes to their positions in BCRX. Headlands Technologies LLC purchased a new position in BioCryst Pharmaceuticals during the 1st quarter worth $32,000. GF Fund Management CO. LTD. purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $33,000. GAMMA Investing LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 1st quarter valued at approximately $62,000. Finally, Family Legacy Financial Solutions LLC acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth approximately $72,000. Hedge funds and other institutional investors own 85.88% of the company's stock. BioCryst Pharmaceuticals Company Profile (Get Free Report)BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.Read MoreFive stocks we like better than BioCryst PharmaceuticalsFollowing Congress Stock Trades3 Long-Term Dividend Buys You Can Get for Under $50Should You Invest in Penny Stocks?How AEP Became a Critical AI Infrastructure PlayWhat is a Death Cross in Stocks?How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?Before you consider BioCryst Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here